Newsletter Tool

Today’s Big News

May 15, 2025

Pathos AI secures $365M series D to fund trial of Novo Nordisk solid tumor drug

FDA delays decision on Biohaven's rare disease drug filing, plans adcomm

Kinase inhibitor biotech Enliven calls time on phase 1 HER2 solid tumor program

RA Capital's biotech incubator lays off staffers: Stat

VC firm reveals plan for 30K-square-foot biotech incubator space in New Jersey

Sanofi hops on the US investment bandwagon with $20B commitment through 2030

Featured

Pathos AI secures $365M series D to fund trial of Novo Nordisk solid tumor drug

By James Waldron

Pathos AI has secured $365 million in series D funds as the artificial-intelligence-powered biotech looks to fund trials of solid tumor drugs sourced from Novo Nordisk and Prelude Therapeutics.

FDA delays decision on Biohaven's rare disease drug filing, plans adcomm

By Nick Paul Taylor

Biohaven is giving investors whiplash. Forty-eight hours after saying its filing was on track, the biopharma revealed the FDA has delayed a decision on its rare disease candidate troriluzole and plans to hold an advisory committee to discuss the application.

Kinase inhibitor biotech Enliven calls time on phase 1 HER2 solid tumor program

By James Waldron

Enliven Therapeutics has decided against taking its phase 1-stage solid tumor drug into further development next year in order to keep resources flowing toward its leukemia candidate.

Medrio CEO on building stability and innovation in clinical trials

RA Capital's biotech incubator lays off staffers: Stat

By Gabrielle Masson

After RA Capital asked its companies to reassess operations, Raven cut an undisclosed number of workers, two sources told Stat.

VC firm reveals plan for 30K-square-foot biotech incubator space in New Jersey

By Darren Incorvaia

The Garden State is looking to grow into the next big biotech hub. The New Jersey Innovation Hub has tapped venture capital firm Portal Innovations to build a 30,000-square-foot incubator lab space in a new life sciences complex under construction in New Brunswick, Portal announced in a May 15 release.

Sanofi hops on the US investment bandwagon with $20B commitment through 2030

By Kevin Dunleavy

Add Sanofi to the list of drugmakers committing billions to bolster their operations in the United States as President Donald Trump continues to ramp up pressure on the biopharma industry. On Wednesday, Sanofi said it will invest at least $20 billion through 2030 to beef up its R&D and manufacturing operations in the U.S.

Julius Clinical and Peachtree BioResearch blossom into CNS-focused global CRO

By Zoey Becker

Netherlands-based Julius Clinical and U.S.-based Peachtree BioResearch Solutions are joining forces to create a global CNS-focused CRO.

WSJ: Feds investigating UnitedHealth for criminal Medicare fraud

By Paige Minemyer

Just days after the company announced a change at the top and the suspension of its 2025 outlook, a new media report suggests its health insurance division is facing a criminal fraud investigation.

Philips survey illustrates trust gaps in AI among patients, providers

By Conor Hale

The medtech’s 10th annual Future Health Index report polled nearly 2,000 professionals and more than 16,000 patients across 16 countries.

Fierce podcasts

Don’t miss an episode

Providers, payers brace for regulatory uncertainty in Q1 

This week on "Podnosis," we break down Q1 earnings season and explore how looming policy shifts—like tariffs, Medicaid cuts and ACA subsidy changes—could reshape the healthcare landscape.